One thousand patients with essential thrombocythemia: the Mayo Clinic experience

Abstract We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between 1967 and 2023: median age 58 years (18–90), females 63%, JAK2/CALR/MPL-mutated 62%/27%/3%, triple-negative (TN) 8%, extreme thrombocytosis (ExT; platelets ≥1000 × 109/L) 26%, leukocytosis (leukocyte cou...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Blood Cancer Journal
المؤلفون الرئيسيون:	Naseema Gangat, Omer Karrar, Aref Al-Kali, Kebede H. Begna, Michelle A. Elliott, Alexandra P. Wolanskyj-Spinner, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Nature Publishing Group 2024-01-01
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41408-023-00972-x

مواد مشابهة

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
حسب: Ayalew Tefferi, وآخرون
منشور في: (2024-03-01)

Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials
حسب: Maymona Abdelmagid, وآخرون
منشور في: (2025-03-01)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
حسب: Ayalew Tefferi, وآخرون
منشور في: (2022-06-01)

Targeted deep sequencing in polycythemia vera and essential thrombocythemia
حسب: Ayalew Tefferi, وآخرون
منشور في: (2016-11-01)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
حسب: Abhishek A. Mangaonkar, وآخرون
منشور في: (2022-02-01)

Targeted deep sequencing in primary myelofibrosis
حسب: Ayalew Tefferi, وآخرون
منشور في: (2016-12-01)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
حسب: Ayalew Tefferi, وآخرون
منشور في: (2023-03-01)

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
حسب: Terra L. Lasho, وآخرون
منشور في: (2018-02-01)

Prognostic impact of <i>SF3B1</i> mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases
حسب: Faiqa Farrukh, وآخرون
منشور في: (2024-03-01)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
حسب: Ayalew Tefferi, وآخرون
منشور في: (2022-09-01)

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
حسب: Ayalew Tefferi, وآخرون
منشور في: (2018-08-01)

Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience
حسب: Naseema Gangat, وآخرون
منشور في: (2022-02-01)

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(<i>DEK::NUP214</i>): The Mayo Clinic experience
حسب: Clifford M. Csizmar, وآخرون
منشور في: (2024-06-01)

<i>CSF3R</i> mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends
حسب: Abiola Bolarinwa, وآخرون
منشور في: (2025-07-01)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
حسب: Maymona G. Abdelmagid, وآخرون
منشور في: (2023-02-01)

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation
حسب: Mrinal M. Patnaik, وآخرون
منشور في: (2019-06-01)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
حسب: Naseema Gangat, وآخرون
منشور في: (2022-06-01)

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days
حسب: Naseema Gangat, وآخرون
منشور في: (2025-04-01)

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons
حسب: Naseema Gangat, وآخرون
منشور في: (2025-05-01)

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
حسب: Ayalew Tefferi, وآخرون
منشور في: (2024-03-01)

Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis
حسب: Animesh Pardanani, وآخرون
منشور في: (2011-01-01)

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases
حسب: Saubia Fathima, وآخرون
منشور في: (2025-03-01)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
حسب: Naseema Gangat, وآخرون
منشور في: (2023-03-01)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
حسب: Ayalew Tefferi, وآخرون
منشور في: (2023-07-01)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
حسب: Naseema Gangat, وآخرون
منشور في: (2022-12-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
حسب: Isla M. Johnson, وآخرون
منشور في: (2025-02-01)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
حسب: Rami Basmaci, وآخرون
منشور في: (2023-08-01)

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”
حسب: K. H. Begna, وآخرون
منشور في: (2022-04-01)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
حسب: Mostafa Abdallah, وآخرون
منشور في: (2023-03-01)

Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases
حسب: Moazah Iftikhar, وآخرون
منشور في: (2025-03-01)

How we diagnose and treat WHO-defined systemic mastocytosis in adults
حسب: Ayalew Tefferi, وآخرون
منشور في: (2008-01-01)

Treatment-relevant misdiagnosis of autoimmune myelofibrosis
حسب: Naseema Gangat, وآخرون
منشور في: (2025-08-01)

<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
حسب: Abhishek A. Mangaonkar, وآخرون
منشور في: (2022-02-01)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
حسب: Bahga Katamesh, وآخرون
منشور في: (2023-08-01)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
حسب: Rimal Ilyas, وآخرون
منشور في: (2023-02-01)

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience
حسب: Giuseppe G. Loscocco, وآخرون
منشور في: (2024-01-01)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
حسب: Amrutha Sai Mittapalli, وآخرون
منشور في: (2023-08-01)

Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine
حسب: Naseema Gangat, وآخرون
منشور في: (2023-11-01)

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
حسب: Mostafa Abdallah, وآخرون
منشور في: (2024-03-01)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
حسب: Muhamad Oum, وآخرون
منشور في: (2023-08-01)